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ABSTRACT
Anti-miRNA antisense inhibitors (AMOs) have
demonstrated their utility in miRNA research and
potential in miRNA therapy. Here we report a mod-
ified AMO approach in which multiple antisense
units are engineered into a single unit that is able
to simultaneously silence multiple-target miRNAs,
the multiple-target AMO or MTg-AMO. We validated
the technique with two separate MTg-AMOs:
anti-miR-21/anti-miR-155/anti-miR-17-5p and anti-
miR-1/anti-miR-133. We first verified the ability of
the MTg-AMOs to antagonize the repressive actions
of their target miRNAs using luciferase reporter
activity assays and to specifically knock down
the levels of their target miRNAs using real-time
RT-PCR methods. We then used the MTg-AMO
approach to identify several tumor suppressors—
TGFBI, APC and BCL2L11 as the target genes for
oncogenic miR-21, miR-155 and miR-17-5p, respec-
tively, and two cardiac ion channel genes HCN2
(encoding a subunit of cardiac pacemaker channel)
and CACNA1C (encoding the a-subunit of cardiac
L-type Ca
2+ channel) for the muscle-specific miR-1
and miR-133. We further demonstrated that the
MTg-AMO targeting miR-21, miR-155 and miR-
17-5p produced a greater inhibitory effect on
cancer cell growth, compared with the regular
single-target AMOs. Moreover, while using the reg-
ular single-target AMOs excluded HCN2 as a target
gene for either miR-1 or miR-133, the MTg-AMO
approach is able to reveal HCN2 as the target for
both miR-1 and miR-133. Our findings suggest the
MTg-AMO as an improved approach for miRNA
target finding and for studying function of miRNAs.
This approach may find its broad application for
exploring biological processes involving multiple
miRNAs and multiple genes.
INTRODUCTION
Discovery of microRNA-1 (miRNA) has revolutionarily
advanced our understanding of the molecular mechanisms
of gene expression regulation (1,2). MiRNAs are a large,
ubiquitous class of endogenous noncoding regulatory
mRNAs of  22-nt long that post-transcriptionally regu-
late the expression of numerous eukaryotic genes. These
molecules act by binding to their target mRNAs, prefer-
entially to the 30-untranslated region (30-UTR) by a partial
base-paring mechanism. In order for a miRNA to give rise
of functional consequences, its 50-end 7–8nt must have
exact complementarity to the target mRNA, the so-
called ‘seed’ region, and partial complementarity with
rest of the sequence. The current model for inhibition
of expression by miRNA suggests that a miRNA either
inhibits translation or induces degradation of its target
mRNA, depending upon the overall degree of comple-
mentarity of the binding site, number of binding sites
and the accessibility of the bindings sites (3–6). MiRNAs
have been increasingly implicated in the control of various
biological processes, including cell diﬀerentiation, cell pro-
liferation, development and apoptosis, and many patho-
logical processes such as cancer, Alzheimer’s disease,
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gested that miRNAs might be viable therapeutic targets
for a wide range of human disease including cancers and
cardiovascular disorders (9,10).
One of the indispensable approaches in miRNA
research as well as in miRNA therapy is inhibition or
loss-of-function of miRNAs. The base-pair interaction
between miRNAs and mRNAs is essential for the function
of miRNAs; therefore, a logical approach of silencing
miRNAs is to use a nucleic acid that is antisense to the
miRNA (9,11–15). These anti-miRNA oligonucleotides
(AMOs) speciﬁcally and stoichiometrically bind, and eﬃ-
ciently and irreversibly silence their target miRNAs.
The AMO approach has been used in numerous studies
to identify many cellular functions of miRNAs and has
been considered a plausible strategy for miRNA therapy
of human disease (9,11–15).
However, it has become clear that a particular condi-
tion may be associated with multiple miRNAs and a
given gene may be regulated by multiple miRNAs. For
example, a study directed to the human heart identiﬁed
67 signiﬁcantly upregulated miRNAs and 43 signiﬁcantly
downregulated miRNAs in failing left ventricles versus
normal hearts (16). No less than ﬁve diﬀerent miRNAs
have been shown to critically involve in cardiac hyper-
trophy (17–21). Similarly, Volinia et al. (22) conducted a
large-scale miRNA analysis on 540 solid tumor samples
including lung, breast, stomach, prostate, colon and pan-
creatic tumors. Their survey revealed 15 miRNAs upre-
gulated and 12 downregulated in human breast cancer
tissues. Similar changes of multiple miRNAs were also
found in other ﬁve solid tumor types. Many of these
miRNAs have been reported to regulate cell proliferation
or apoptosis and some of them have been considered
oncogenic miRNAs or tumor suppressor miRNAs.
These properties of miRNA regulation may well create
some uncertainties of outcomes by applying the AMO
technology to silence miRNAs since knocking down
a single miRNA may not be suﬃcient, and certainly
not optimal, to achieve the expected interference of cel-
lular process and gene expression which are regulated by
multiple miRNAs. These facts also prompted us to raise
several pertinent questions. If targeting a single miRNA
is adequate for tackling a pertinent pathological condi-
tion? If simultaneously targeting multiple miRNAs rele-
vant to a particular condition oﬀers an improved
approach than targeting a single miRNA using the reg-
ular AMO techniques? How can we concomitantly
silence multiple miRNAs to achieve an interference of
a cellular function? To answer these questions, we devel-
oped an innovative strategy, the multiple-target AMO
technology, which confers a single AMO fragment the
capability of targeting multiple miRNAs. We function-
ally validated the technology with oncogenic miRNAs
miR-21, miR-155 and miR-17-5p, and the muscle-speciﬁc
miRNAs miR-1 and miR-133, by demonstrating the
superiority of MTg-AMOs over the regular AMOs in
miRNA targeting. Using this new technology, we were
also able to identify several new target genes for these
miRNAs.
MATERIALS AND METHODS
Neonatal rat cardiomyocyte culture
The procedures were essentially the same as previous
described (23). One- to two-day-old rats were decapitated,
hearts aseptically removed, dissected, minced and exposed
overnight to 0.05% trypsin (48C). The next day, cells were
dissociated with collagenase (Worthington), centrifuged
(500g,4 8C), and preplated in culture ﬂasks (60min,
378C). Subsequently, nonattached cells (myocytes) were
plated on 24-well plates in DMEM/F-12 medium
(Invitrogen) containing 10% FBS, 0.1mM L-ascorbic
acid, 0.1mM bromodeoxyuridine (Sigma), insulin-
transferring-sodium selenite (Invitrogen) and 10
–9M triio-
dothyronine. Over 90% of cells in culture were observed
to beat. Use of animals was in accordance with the reg-
ulations of the ethic committees of Harbin Medical
University and Montreal Heart Institute.
Cell culture
HEK293 cells (human embryonic kidney cell line) and
MCF-7 (human breast cancer cell line) were purchased
from American Type Culture Collection (ATCC,
Manassas, VA). The cells were cultured in Dulbecco’s
Modiﬁed Eagle Medium (DMEM). The culture was sup-
plemented with 10% fetal bovine serum and 100mg/ml
penicillin/streptomycin.
Synthesis ofmiRNAs and anti-miRNA inhibitorantisense
oligonucleotides
Human mature miRNAs (miR-21, miR-155, miR-17-5p,
miR-1 and miR-133) were synthesized by Invitrogen.
These mature miRNAs were nonchemically modiﬁed
and carried the 2-nt overhands as deﬁned in miRBase
(http://microrna.sanger.ac.uk/registry/; the Wellcome
Trust Sanger Institute). The two strands of each miRNA
were synthesized separately and underwent annealing
steps to a duplex. The sequences of anti-miRNA antisense
inhibitor oligodeoxyribonucleotides (AMOs) are the exact
antisense copies of their mature miRNA sequences and
the multiple-target AMOs (MTg-AMOs) were synthesized
by Integrated DNA Technologies, Inc. (IDT). The MTg-
AMOs tested in this study were designed to integrate
the AMOs against miR-21, miR-155 and miR-17-5p into
one AMO (MTg-AMO21/155/17) and those against miR-1
and miR-133 into another antisense fragment (MTg-
AMO1/133). An 8-nt linker (underlined letters in
Figures 1A and 2A) was inserted to connect the two adja-
cent antisense units and 5nt at both ends were locked with
methylene bridges (LNA), with the rest of residues at the
form of DNA.
Construction of chimeric miRNA binding site–luciferase
reporter vectors
The sequence of a fragment containing exact binding sites
for all ﬁve miRNAs (miR-21/miR-155/miR-17-5p/miR-1/
miR-133, Supplementary Figure 1) was synthesized
by Invitrogen and the sense and antisense strands of
the oligonucleotides were annealed by adding 2mgo f
each oligonucleotides to 46ml of annealing solution
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Figure 1. Comparison of anti-miRNA antisense inhibitor oligonucleotides (AMO) and multiple target AMO (MTg-AMO) approaches as tools for
miRNA research. (A) Sequences of the AMOs and MTg-AMOs used in our experiments. All AMOs and MTg-AMOs were chemically modiﬁed to
have 5nt at both ends locked with methylene bridges. An 8-nt linker (underlined letters) was inserted to connect the two adjacent antisense units. The
base substitution mutations (lower bold case) were introduced into the ﬁrst 8nt from the 50-end of each antisense units (capital bold letters) to
construct a negative control MTg-AMO. (B) Comparison of MTg-AMO21/155/17 (10nM) and the regular AMOs (AMO-21, AMO-155 and AMO-
17; 10nM each) in their silencing eﬀects induced by miR-21, miR-155, and miR17-5p (10nM), respectively, as determined by luciferase reporter
activities in HEK293 cells. (C) Comparison of MTg-AMO21/155/17 and the regular AMOs (AMO-21 and AMO-155) in their silencing eﬀects
induced by coapplication of miR-21 and miR-155 (miR-21+miR-155), as determined by luciferase reporter activities in HEK293 cells.
(D) Comparison of MTg-AMO21/155/17 and the regular AMOs (AMO-21 and AMO-17) in their silencing eﬀects induced by co-application of
miR-21 and miR-17-5p (miR-21+miR-17), as determined by luciferase reporter activities in HEK293 cells. (E) Comparison of MTg-AMO21/155/17
and the regular AMOs (AMO-21, AMO-155 and AMO-17) in their silencing eﬀects induced by co-application of miR-21, miR-155, and miR17-5p
(miR-21+miR-155+miR-17), as determined by luciferase reporter activities in HEK293 cells. AMO-Mix: mixture of AMO-21, AMO-155 and
AMO-17, 10nM each; NC MTg-AMO: negative control MTg-AMO21/155/17.
 P<0.05 versus Ctl; + P<0.05 versus AMO-Mix; unpaired Student
t-test; n=5 batches of cells for each group. (F) Veriﬁcation of presence of miR-21, miR-155, and miR17-5p in HeLa cervical carcinoma cells,
measured by quantitative real-time RT-PCR. The data were normalized to the value of miR-1.( G) Comparison of eﬀects of MTg-AMO21/155/17 or
the regular AMOs (AMO-21, AMO-155 and AMO-17) alone on luciferase reporter activities in HeLa cells. Note that all AMOs signiﬁcantly
enhanced luciferase activity presumably by silencing endogenous miRNAs miR-21, miR-155, and miR17-5p.
 P<0.05 versus Ctl; unpaired
Student t-test; n=6 batches of cells for each group.
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2mM Mg-acetate) and incubated at 908C for 5min and
then at 378C for 1h. The annealed oligonucleotides were
then inserted into HindIII and SpeI sites within the
30-UTR luciferase gene in the pMIR-REPORT
TM lucifer-
ase miRNA expression reporter vector (Ambion, Inc.)
(23,24).
The 30-UTR of transforming growth factor BI (TGFBI),
a fragment (8590–9590bp; accession no. NM_000358)
containing the putative target site for miR-155 within
the 30-UTR of APC, a fragment (2515–2815bp; accession
no. NM_000038) containing the putative target site
for miR17-5p within the 30-UTR of BCL2L11, a fragment
(6685–6885bp; accession no. NM_138621) containing the
predicted miR-133 site within the 30-UTR of CACNA1C
and the 30-UTR of HCN2 were inserted, respectively, into
the 30-UTR region of the pMIR-REPORT
TM luciferase
miRNA expression reporter vector (Ambion, Inc.) to
create the chimeric luciferase-miRNA vectors (25,26).
Mutagenesis
Nucleotide-substitution mutations (as shown in
Figure 1A) were carried out by direct oligomers synthesis
by IDT. The substitution nucleotides were so designed to
avoid producing new binding sites for other miRNAs.
All constructs were sequencing veriﬁed.
In vitro transfection ofmiRNAs and luciferase assay
After a 24-h starvation in serum-free medium, cells
(1 10
5/well) were transfected with 1mg the miRNAs,
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Figure 2. Comparison of anti-miRNA antisense inhibitor oligonucleotides (AMO) and multiple target AMO (MTg-AMO) approaches as tools for
miRNA research. (A) Sequences of the AMOs and MTg-AMOs used in the experiment. An 8-nt linker (underlined letters) was inserted to connect
the two adjacent antisense units and 5nt at both ends were locked with methylene bridges. The base substitution mutations (lower bold case) were
introduced into the ﬁrst eight nucleotides from the 50-end of each antisense units (capital bold letters) to construct a negative control MTg-AMO.
(B) Comparison of MTg-AMO1/133 (10nM) and the regular AMOs (AMO-1 and AMO-133; 10nM each) in their silencing eﬀects induced by miR-1
and miR-133 (10nM), respectively, as determined by luciferase reporter activities in HEK293 cells. (C) Comparison of MTg-AMO1/133 and the
regular AMOs (AMO-1 and AMO-133) in their silencing eﬀects induced by co-application of miR-1 and miR-133 (miR-1+miR-133), as determined
by luciferase reporter activities in HEK293 cells. AMO-Mix: mixture of AMO-1 and AMO-133, 10nM each; NC MTg-AMO: negative control MTg-
AMO1/133
 P<0.05 versus Ctl; unpaired Student t-test; n=5 batches of cells for each group. (D) Veriﬁcation of presence of miR-1 and miR-133 in
H9c2 cells, measured by quantitative real-time RT-PCR. The data were normalized to the value of miR-21.( E) Comparison of eﬀects of MTg-
AMO1/133 or the regular AMOs (AMO-1 and AMO-133) alone on luciferase reporter activities in H9c2 cardiac cells. Note that all AMOs
signiﬁcantly enhanced luciferase activity presumably by silencing endogenous miRNAs miR-1 and miR-133.
 P<0.05 versus Ctl; unpaired
Student t-test; n=5 batches of cells for each group.
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(Invitrogen), according to the manufacturer’s instructions
(25,26).
For luciferase assay, cells were co-transfected with 1mg
PGL3–target DNA (ﬁreﬂy luciferase vector) and 0.1mg
PRL-TK (TK-driven Renilla luciferase expression
vector) with lipofectamine 2000. Following transfection
(48h), luciferase activities were measured with a dual luci-
ferase reporter assay kit (Promega) on a luminometer
(Lumat LB9507).
Quantification of mRNA andmiRNA levels
For quantiﬁcation of transcripts of TGFBI, APC,
BCL2L11, HCN2 and CACNA1C, conventional real-
time RT-PCR was carried out with total RNA samples
extracted from rat ventricular wall of experimental myo-
cardial infarction and treated with DNase I (23,24).
TaqMan quantitative assay of transcripts was performed
with real-time two-step RT-PCR (GeneAmp 5700, PE
Biosystems), involving an initial RT with random primers
and subsequent PCR ampliﬁcation of the targets.
Expression level of GAPDH was used as an internal
control.
The mirVana
TM qRT-PCR miRNA Detection Kit
(Ambion) was used in conjunction with real-time PCR
with SYBR Green I for quantiﬁcation of miRNA tran-
scripts in our study, following the manufacturer’s instruc-
tions. The total RNA samples were isolated with
Ambion’s mirVana miRNA Isolation Kit, from human
left ventricular preparations from patients with myocar-
dial infarction due to coronary artery disease (CAD) and
from rat myocardium. Reactions contained mirVana
qRT-PCR Primer Sets speciﬁc for human or rat miR-1s
and human 5S rRNA as positive controls. qRT-PCR was
performed on a 96-well StepOnePlus
TM system (A&B
Applied Biosystems) for 40 cycles. We ﬁrst determined
the appropriate cycle threshold (Ct) using the automatic
baseline determination feature. We then performed disso-
ciation analysis (melt-curve) on the reactions to identify
the characteristic peak associated with primer-dimers in
order to separate from the single prominent peak repre-
senting the successful PCR ampliﬁcation of miRNAs.
Fold variations in expression of miRNAs between RNA
samples were calculated.
Western blot
The protein samples were extracted from rat left ventricu-
lar wall, with the procedures essentially the same as
described in detail elsewhere (25,26). The protein content
was determined with Bio-Rad Protein Assay Kit (Bio-
Rad, Mississauga, ON, Canada) using bovine serum albu-
min as the standard. Protein sample ( 30mg) was fractio-
nated by SDS–PAGE (7.5–10% polyacrylamide gels) and
transferred to PVDF membrane (Millipore, Bedford,
MA). The sample was incubated overnight at 48C with
primary antibodies for TGFBI, APC and BCL2L11
(Santa Cruz), and for HCN2 and Cav1.2 (Alomone
Labs). Bound antibodies were detected using the chemilu-
minescent substrate (Western Blot Chemiluminescence
Reagent Plus, NEN Life Science Products, Boston,
USA). Western blot bands were quantiﬁed using
QuantityOne software by measuring the band intensity
(Area OD) for each group and normalizing to
GAPDH (anti-GAPDH antibody from Research
Diagnostics Inc) as an internal control. The ﬁnal results
are expressed as fold changes by normalizing the data to
the control values.
Data analysis
Group data are expressed as mean S.E. Statistical com-
parisons (performed using ANOVA followed by
Dunnett’s method) were carried out using Microsoft
Excel. A two-tailed P<0.05 was taken to indicate a sta-
tistically signiﬁcant diﬀerence. Nonlinear least square
curve ﬁtting was performed with GraphPad Prism 3.1.
RESULTS AND DISCUSSION
MTg-AMOs inmiRNA targetfinding
We ﬁrst designed three regular AMOs (AMO-21, AMO-
155 and AMO-17) exactly antisense to miR-21, miR-155,
and miR-17-5p, respectively. We choose miR-21, miR-155,
and miR-17-5p as the miRNA targets for testing our
approach since they are proven oncogenic miRNAs over-
expressing in several solid cancers (22,27). We then gener-
ated another AMO, which was engineered to contain the
three regular AMO units (Figure 1A)that could presum-
ably target all the three miRNAs. For convenience, we
named this longer AMO multiple-target AMO21/155/17 or
MTg-AMO21/155/17. In addition, a negative control MTg-
AMO21/155/17 (Figure 1A) was also constructed as a neg-
ative control for the eﬀects of MTg-AMO21/155/17.
We went on to test the ability of these MTg-AMOs to
inactivate their respective target miRNAs by luciferase
reporter assays. An artiﬁcially designed fragment contain-
ing the binding sequences for all ﬁve target miRNAs (miR-
21, miR-155, miR-17-5p, miR-1 and miR-133) was inserted
into the 30-UTR of the luciferase gene in the luciferase
reporter vector (Supplementary Figure 1 online).
Luciferase activities were measured 48h after transfection
of the vector together with various constructs (as speci-
ﬁed) into the HEK293 cells. As shown in Figure 1B, MTg-
AMO21/155/17 (10nM) was able to abolish the inhibitory
eﬀect on luciferase activity, induced by any of miR-21,
miR-155 and miR-17-5p alone (10nM) or any combina-
tions of the three miRNAs at 10nM each (Figure 1C–E),
while the negative control MTg-AMO21/155/17 (10nM)
failed to produce any eﬀects. By comparison, the regular
AMO targeting a single miRNA aﬀected the luciferase
activity only when co-transfected with its target miRNA.
Also striking is that MTg-AMO21/155/17 produced signiﬁ-
cantly greater repressive eﬀects than the mixture of the
regular AMOs AMO-21, AMO-155 and AMO-17at
10nM each (Figure 1D), which is labeled ‘AMO-Mix’ in
the ﬁgures. The negative control MTg-AMO21/155/17 did
not produce any signiﬁcant eﬀects (Figure 2C–E). To
examine whether the AMOs could also exert silencing
eﬀects on endogenous miRNAs in HeLa cervial carci-
noma cells, we ﬁrst conﬁrmed the presence of
mature miR-21, miR-155 and miR-17-5p in these cells
PAGE 5 OF 10 Nucleic AcidsResearch, 2009, Vol.37,No. 3 e24(Figure 1F), and then we looked at the luciferase activities
after co-transfection of the vector and MTg-AMO21/155/
17, AMO-21, AMO-155 or AMO-17. As expected, these
AMOs all were able to signiﬁcantly increase luciferase
activities (Figure 1G), presumably by knocking down
the endogenous miR-21, miR-155 and miR-17-5p in
HeLa cells.
In order to investigate whether the enhanced eﬀects
of MTg-AMO could be reproduced on other target
miRNAs, we designed another MTg-AMO fragment tar-
geting miR-1 and miR-133 (Figure 2A), the muscle-speciﬁc
miRNAs crucial to myogenesis and cardiac hypertrophy
and ischemic arrhythmogenesis (19–22,24–26,28,29). Here
we called this fragment MTg-AMO1/133. As illustrated in
Figure 2B and C, MTg-AMO1/133 (10nM) antagonized
the repressive actions produced by either miR-1 or miR-
133 (10nM) in luciferase assays. MTg-AMO1/133 also
reversed the inhibitory eﬀects elicited by co-application
of miR-1 and miR-133, with a greater potency than the
mixture of AMO-1 and AMO-133 (10nM each,
Figure 2C). We then went on to verify the ability of
MTg-AMO1/133, AMO-1 and AMO-133 to inhibit the
repressing eﬀects induced by endogenous miR-1 and
miR-133 in H9c2 rat ventricular cells. We ﬁrst demon-
strated the presence of miR-1 and miR-133 in H9c2 cells
(Figure 2D), and then we observed the luciferase activities
after co-transfection of the vector and MTg-AMO1/133,
AMO-1 and AMO-133. As shown in Figure 2E, these
AMOs applied alone each signiﬁcantly enhanced lucifer-
ase activities.
To verify the luciferase results and to search the target
genes of the ﬁve miRNAs using our MTg-AMO strategy,
we ﬁrst performed computational prediction using the
miRBase hosted by the Wellcome Trust Sanger Institute.
We identiﬁed three tumor suppressor genes—TGFBI,
APC and BCL2L11 as potential targets for miR-21,
miR-155 and miR-17-5p, respectively, which carry in
their 30-UTRs the binding sites for the three miRNAs
(Supplementary Figure 2 online). We then evaluated the
eﬀects of MTg-AMO21/155/17 on the protein levels of these
three candidate target genes. As depicted in the left and
middle panels of Figure 3A, MTg-AMO21/155/17 (10nM)
concordantly increased the levels of tumor suppressor
genes TGFBI, APC and BCL2L11 in MCF-7 human
breast cancer cells which express abundant endogenous
miR-21, miR-155 and miR-17-5p (30) (Supplementary
Figure 3 online). As expected, the negative control MTg-
AMO21/155/17 failed to elicit any signiﬁcant eﬀects. The
speciﬁcities of the regular individual AMOs on their
respective target genes were veriﬁed with the data shown
in the right panel of Figure 3A.
Similarly, through theoretical analysis, we identiﬁed
two ion channel genes HCN2 (encoding a subunit of car-
diac pacemaker channel) (26) and CACNA1C (encoding
the a-subunit of cardiac L-type Ca
2+ channel) (31) as
potential targets for miR-1 and miR-133 since the
30-UTR of HCN2 mRNA contains the putative binding
sites for both miR-1 and miR-133, and that of CACNA1C
mRNA has a putative binding sequence for miR-133 only
(Supplementary Figure 2 online). We observed that trans-
fection of MTg-AMO1/133 remarkably increased the
protein levels of the two ion channels in isolated neonatal
rat ventricular myocytes which are known to express
endogenous miR-1 and miR-133 (23). Notably, neither
AMO-1 nor AMO-133 alone produced signiﬁcant eﬀects
on the protein level of HCN2, indicating that use of the
regular AMOs can yield false-negative results when a gene
is simultaneously regulated by more than one miRNA.
Co-transfection of AMO-1 and AMO-133 (AMO-Mix)
also increased the HCN2 protein levels, but to a signi-
ﬁcantly less extent compared to MTg-AMO1/133
(Figure 3B).
To verify that TGFBI, APC and BCL2L11 are indeed
the cognate targets for miR-21, miR-155 and miR-17-5p,
and HCN2 and CACNA1C the cognate targets for miR-1
and miR-133, respectively, we inserted the 30-UTRs or
fragments within the 30-UTRs containing the predicted
miRNA-binding sites of the genes into the 30-UTR of
the luciferase reporter vector. The chimeric vectors con-
taining the 30-UTRs of TGFBI, APC and BCL2L11,
along with other constructs as speciﬁed in Figure 3C,
were co-transfected into the HEK293 cells. MTg-
AMO21/155/17 but not the negative control MTg-AMO21/
155/17 abolished the depression of luciferase activities
consequent to the interactions between the 30-UTRs
and the miRNAs, whereas none of the AMOs alone
was suﬃcient to reverse completely the inhibition in
the presence of miR-21, miR-155 and miR-17-5p together.
Similar results were observed with the MTg-AMO1/133
and the 300-UTRs of HCN2 and CACNA1C genes
(Figure 3D).
The MTg-AMOs did not signiﬁcantly aﬀect the mRNA
levels of their targets genes (Figure 4A), neither did the
regular AMOs (data not shown).
To verify that the eﬀects of MTg-AMO21/155/17 and
MTg-AMO1/133 were indeed consequent to interacting
with their target miRNAs, we quantiﬁed the miRNA
levels. Consistent with previous studies showing degrada-
tion of target miRNAs by AMOs (11,13), we found that
these MTg-AMOs remarkably reduced their target
miRNAs (Figure 4B), and so did the regular AMOs
(Figure 4C). Noticeably, the MTg-AMOs and the regular
AMOs used in our study did not show cross-reactions
with nontarget miRNAs. For example, MTg-AMO21/155/
17 only reduced miR-21, miR-155 and miR-17-5p levels
without altering miR-1 and miR-133 levels, detected by
real-time RT-PCR; vice versa, MTg-AMO1/133 reduced
only miR-1 and miR-133 levels without altering miR-21,
miR-155 and miR-17-5p levels, indicating the speciﬁcities
of actions of the MTg-AMOs.
It has recently been noticed that reduction of miRNA
level by AMO could be simply due to the interference of
AMO with miRNA detection when using northern blot
with DNA probes, but not due to miRNA degradation
(32,33). To see whether the miRNA reduction detected
by real-time RT-PCR in our experiments was also
ascribed to the same mechanism, we carried out another
study following the procedure described by Fabani
and Gait (33). We spiked MTg-AMO21/155/17 into lysate
from control untreated HeLa cells at a series of con-
centrations ranging from 1 to 30nM before RNA puriﬁca-
tion involving denaturing conditions, and then measured
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isolated RNA sample. As shown in Figure 4E, AMO21/
155/17 produced concentration-dependent reduction of the
levels, indicating that the miRNAs in the AMO21/155/17:
miRNA complex were not directed into the RNA fraction
during puriﬁcation. Similar results were obtained with
MTg-AMO1/133 on miR-1 and miR-133 in lysate from
control untreated H9c2 cells (Figure 4F). Hence, the
apparent reduction of miRNA levels revealed by qRT-
PCR should not be used as evidence of a miRNA degra-
dation pathway, but merely indicating the binding of the
MTg-AMOs to the targeted miRNAs leading to inhibition
of miRNA activities (33).
MTg-AMO enhances the efficacy tosuppresses cancer
cell growth
Since MTg-AMO21/155/17 was designed to target the three
most frequently overexpressed oncogenic miRNAs in
many cancers (21,22), it was expected to suppress cancer
cell growth. To this end, we investigated the eﬀects
of MTg-AMO21/155/17 on viability of MCF-7 cells. MTg-
AMO21/155/17 (10nM) diminished the survival rate to
 18% of the values from control group or negative con-
trol MTg-AMO21/155/17 group, whereas in order to reach
signiﬁcant eﬀects with the regular AMOs, the concen-
tration of each AMO had to be elevated to 100nM
(Figure 4D). Most noticeably, co-transfection of
Figure 3. MTg-AMO as an improved AMO approach for miRNA target ﬁnding. (A and B) Western blot analysis of the protein levels of TGFBI,
APC BCL2L11, HCN2 and Cav1.2. For MTg-AMO21/155/17, human breast cancer MCF-7 cells were used and for MTg-AMO1/133, cultured neonatal
rat ventricular myocytes were used. NC and NC MTg-AMO: negative control MTg-AMO. The relevant miRNA for each target mRNA is speciﬁed
above the name of the target mRNA in western blot images.
 P<0.05 versus Ctl; +P<0.05 versus MTg-AMO; unpaired Student t-test; n=3 for
each group. (C and D) Silencing eﬀects of MTg-AMO21/155/17 and MTg-AMO1/133 in HEK293 cells, reported by luciferase vector containing the 300-
UTRs of the ﬁve genes. The cells were co-transfected with the chimeric vectors carrying miR-21, miR-155, and miR17-5p, miR-1 and miR-133 sites,
the miRNAs and the MTg-AMOs, and the luciferase activities were measured 48h after transfection. The concentration of each construct was 10nM.
 P<0.05 versus Ctl, unpaired Student t-test; n=5 batches of cells for each group.
PAGE 7 OF 10 Nucleic AcidsResearch, 2009, Vol.37,No. 3 e24Figure 4. Veriﬁcation of the mode of actions of MTg-AMOs. (A) Eﬀects of AMOs and MTg-AMOs on mRNA levels of their targets genes,
determined by real-time qRT-PCR methods. Tri-miRNAs: co-transfection of miR-21, miR-155 and miR-17-5p at 10nM each; Bi-miRNAs: co-
transfection of miR-1 and miR-133 at 10nM each. Note that the mRNA levels of the target genes, as speciﬁed, were not aﬀected by the
miRNAs. (B) Eﬀects of MTg-AMOs on the activities of their target miRNAs. Note that the MTg-AMOs nearly abolished their target miRNAs
but did not aﬀect the non-target miRNAs.
 P<0.05 versus Ctl. n=5 for each group. (C) Veriﬁcation of the speciﬁcities of individual AMOs against
their corresponding miRNAs. Data shown are the eﬀects of AMO-1 and AMO-155 on the activities of various miRNAs. Note that AMO-1 and
AMO-155 only knocked down their targeted miRNAs without aﬀecting other miRNAs tested. (D) MTg-AMO as a potential strategy for miRNA
therapy. Shown are the eﬀects of each AMO (100nM), AMO-Mix1 (a mixture of AMO-21, AMO-155 and AMO-17at 10nM each), AMO-Mix2
(a mixture of AMO-21, AMO-155 and AMO-17at 3.3nM each), MTg-AMO21/155/17 (10nM) and negative control (NC) MTg-AMO21/155/17
(10nM) on cell survival, as determined by MTT assay, in MCF-7 cells.
 P<0.05 versus Ctl;
+P<0.05 versus MTg-AMO21/155/17, unpaired
Student t-test; n=5 batches of cells for each group. (E) Measurement of miR-21, miR-155 and miR-17-5p levels by real-time RT-PCR methods.
MTg-AMO21/155/17 amounts corresponding to 1-, 3-, 10- and 30-nM transfections were spiked into HeLa cell lysate (one lysate equals one well on
a six-well plate) before RNA extraction (33). miR-1 level was used as a control for normalization. (F) Measurement of miR-1 and miR-133 levels by
real-time RT-PCR. MTg-AMO1/133 amounts corresponding to 1-, 3-, 10- and 30-nM transfections were spiked into H9c2 cell lysate as described in
(E). miR-21 level was used as a control for normalization.
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of 30nM, AMO-Mix1) or 3.3nM each (a total of 10nM,
AMO-Mix2) produced signiﬁcantly smaller decreases in
cell survival than 10nM MTg-AMO21/155/17 (Figure 4D).
In summary, using the MTg-AMO approach, we have
been able to identify several tumor suppressors as the
target genes for oncogenic miR-21, miR-155 and miR-
17-5p and two cardiac ion channel genes for the muscle-
speciﬁc miR-1 and miR-133. This study also represents the
ﬁrst to reveal the cardiac L-type Ca
2+ channel a-subunit
gene CACNA1C gene as a target gene for miR-133 action.
The improvement of the MTg-AMO approach over
the regular single-target AMO approach is reﬂected by
two ﬁndings. First, MTg-AMO21/155/17 demonstrated a
strengthened ability to inhibit cancer cell growth com-
pared with the single-target AMOs or combination of
these AMOs. Second, the MTg-AMO approach is able
to reveal HCN2 gene as a target for miR-1 and miR-133,
which is otherwise concealed by the single-target AMO
approach (Figure 3). There are two possible explanations
for the superiority of the MTg-AMO approach over the
regular AMO approach. First, the covalent linkage
ensures co-delivery of diﬀerent AMOs. Given the compa-
rable cell targeting rates for the MTg-AMO and the indi-
vidual AMOs, only the MTg-AMO approach ensures that
the transfected cells received all relevant miRNA antago-
nists for gene targeting and proliferation inhibition.
Another possible explanation is that annealing rate con-
stants describing the annealing reaction between comple-
mentary nucleic acids strongly correlate with the length of
the two complementary sequences. On the average, longer
sequences anneal faster than shorter sequences (34,35).
Therefore, the MTg-AMO might anneal faster with the
miRNAs compared to the smaller individual AMO.
Future studies are needed to verify these notions.
The beauty of this MTg-AMO ‘single-agent, multiple-
targets’ strategy is that it can be either homogeneous car-
rying multiple identical antisense units targeting a speciﬁc
miRNA to enhance the antagonizing eﬀect or heteroge-
neous with multiple distinct antisense units targeting dif-
ferent miRNAs to expand targeting capacity. Considering
that a given mRNA is regulated by multiple miRNAs and
concordantly targeting multiple miRNAs might be
required to achieve optimal interference of that gene, the
MTg-AMO approach may be superior to the regular
AMO technique. Just taking cancer therapy as an exam-
ple, an MTg-AMO can be designed to target the miRNAs
that are involved in tumor cell proliferation, cell death,
metastasis and vascular angiogenesis. Targeting any one
of these aspects may not be optimal for controlling tumor-
igenesis and progression. Interfering concomitantly with
all these processes should expectedly yield a better anti-
cancer outcome. Our ﬁndings therefore suggest the MTg-
AMO approach as a useful tool in miRNA target ﬁnding
and the potential of this novel strategy as a miRNA
therapy for cancer and cardiac disorders.
We consider the present work still preliminary; to com-
pletely validate the MTg-AMO technology as a gene ther-
apy strategy, many important issues are to be unresolved.
Future studies are warranted to test more MTg-AMOs
for the advantages of this approach and to get insight
into more detailed mechanisms for the actions of MTg-
AMOs. Dose–response actions were not evaluated in this
study due to the diﬃculties of optimizing the ratio of con-
struct/lipofectamine to ensure eﬃcient transfection. The
optimal combination of targets for an MTg-AMO remains
unknown. In this study, we tested ‘two-in-one’ and ‘three-
in-one’ MTg-AMOs. In theory, ‘N-in-one’ MTg-AMOs
(N could be any number of AMO units) can be designed
to include more relevant AMOs. More rigorous studies
are warranted to deﬁne the optimal combination of
length of MTg-AMOs to optimize desired eﬀectiveness.
This work does not allow us to draw any conclusions as
to what the optimal organization is for multiple AMO
units (the order of the units) to be placed in a single
MTg-AMO molecule.
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